Drug News

Generic Drugmaker Stada has Spun off Russian Business

In recent news, the generic drugmaker Stada has reportedly separated its Russian business, establishing a distinct entity named Nizhpharm, as per information from the Welt am Sonntag newspaper. A spokesperson from Stada confirmed this development, stating that Nizhpharm will now function independently and autonomously.

As of now, Stada has chosen not to comment on the specifics of the report. However, it’s worth noting that the private equity owners of Stada, recognized for selling a range of consumer healthcare products including painkillers and sunscreen lotions, along with biosimilar and generic drugs, are said to be contemplating strategic options. These options include the potential sale of the company or an initial public offering (IPO), according to sources familiar with the matter.

The situation suggests a strategic move by Stada to reorganize its operations, particularly in the Russian market, and explore different avenues for the future, including the possibility of a sale or IPO.


Joan David-Leonhard

Joan David Leonhard is a recent Pharm.D graduate with a strong passion for the pharmaceutical industry and a particular interest in pharmaceutical media and communication. Her brief internship experience includes roles in pharmacy where she built strong patient-pharmacist relationships and a pharmaceutical media internship where she actively contributed to drug information articles, blog posts, social media engagement, and various media projects.
Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker